Navigation Links
Wilson Therapeutics Announces Presentation Of WTX101-201 Phase 2 Study At The EASL 50th International Liver Congress 2015
Date:4/16/2015

STOCKHOLM, April 16, 2015 /PRNewswire/ -- Wilson Therapeutics AB, a development stage biopharmaceutical company, today announced that a poster of the company's ongoing Phase 2 clinical trial for WTX101-201 will be presented at the upcoming annual meeting of the European Association for the Study of the Liver (EASL), or the 50th International Liver Congress 2015, taking place in Vienna April 22-26. The poster, titled "WTX101-201: Phase 2 Study of Bis-choline Tetrathiomolybdate in Newly Diagnosed Wilson Disease Patients," will be presented in the Clinical Trials in Progress session on April 25.

WTX101-201 is a Phase 2 clinical trial evaluating the efficacy and safety of WTX101 using an individualized dosing regimen in up to 30 newly-diagnosed patients with Wilson Disease. The study is being conducted at sites in the U.S. and Europe, and will follow patients on WTX101 for six months.

"We are very excited to be involved in the WTX101-201 study, the first clinical trial to evaluate a new therapy for Wilson Disease in Europe for more than a decade," said Karl-Heinz Weiss, MD, Associate Professor, Liver Cancer Center, University of Heidelberg. "Based on earlier clinical studies with tetrathiomolybdate in people with neurologic Wilson Disease, WTX101 holds great promise to mitigate the neurologic damage from Wilson Disease, so we are delighted it is available for study participants."

About WTX101
WTX101 is the proprietary bis-choline salt of tetrathiomolybdate, which has been evaluated for various indications in clinical studies involving over 500 patients, including 120 patients with Wilson Disease. Through its unique mechanism of action, tetrathiomolybdate has been shown to rapidly lower and control copper levels in both Wilson Disease and other patients. Previous data also suggest that tetrathiomolybdate may stabilize neurological function and reduce the risk of neurological deterioration after initiation of treatment in Wilson Disease patients with neurological involvement. WTX101 has been shown to lower and maintain copper levels with once or twice daily oral dosing. WTX101 has received orphan drug designation in both the United States and the European Union.

About Wilson Disease
Wilsons Disease is a rare autosomal recessive disorder caused by mutations in the ATP7B gene resulting in deficient production of the copper-transporter ATPase-2. Deficient or absent production of ATPase-2 leads to impaired incorporation of Cu into ceruloplasmin and impairment of biliary Cu excretion which allows copper to accumulate in the body. The build-up of copper in liver, brain, kidneys and other tissues of Wilson Disease patients produces significant organ damage and dysfunction. Untreated or inadequately treated disease can result in brain damage, liver failure and death. The overall prevalence of Wilson Disease is estimated to be 1-2 in 30,000.

About Wilson Therapeutics
Wilson Therapeutics is a privately-held biopharmaceutical company focused on improving the lives of patients with Wilson Disease through development of new treatment options and support for increased awareness and education about Wilson Disease. The Company's lead product candidate, WTX101, is currently in clinical development as a treatment for Wilson Disease. Investors in Wilson Therapeutics include Abingworth, HealthCap, MVM Life Science Partners and Neomed. Visit www.wilsontherapeutics.com for more information.

Contact:

Jonas Hansson

CEO

+46709441877

OR

Ami Knoefler

Spark BioComm LLC

+ 1 650 739 9952

 


'/>"/>
SOURCE Wilson Therapeutics
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Varian Imaging Components President Robert Kluge Announces Plans to Retire; Varian CEO Dow Wilson Names Sunny Sanyal as Kluges Successor
2. Celebrity Attorney Mychal Wilson Victorious Against Biotronik, Inc. in Winning Yet Another Whistleblower Case for the American Taxpayer
3. Wilson Therapeutics Announces Start Of Phase 2 Study To Evaluate The Efficacy And Safety Of WTX101 In Newly Diagnosed Wilson Disease Patients
4. NanoSmart Welcomes Reg Wilson, Founder of EPIC Wealth, to Advisory Board
5. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
6. Novelos Therapeutics Provides Product Pipeline Update
7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
8. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
9. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
10. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
11. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2018)... SEDONA, Ariz. (PRWEB) , ... December 06, 2018 ... ... a new website and with it, more answers for the millions of Americans ... Different than the other available treatment facilities, the renowned Alternative to Meds Center ...
(Date:12/5/2018)... ... December 05, 2018 , ... Smile Brands Inc. has ... row moving from the 43rd to 25th position on the list of the ... now in its 11th year, relies solely on the input of employees, who elect ...
(Date:12/5/2018)... ... December 05, 2018 , ... HealthChannels, the ... the hiring of Dr. Tony Andrulonis, MBA to lead company-wide operational performance initiatives. ... 20,000 medical scribes and support staff. Prior to joining HealthChannels, Andrulonis held leadership ...
Breaking Medicine Technology:
(Date:12/5/2018)... ... December 05, 2018 , ... You can now experience two cutting ... LTRMN , is a powerhouse in the cannabis industry with several brands including ... is an industry leading, award winning , botanical terpene company that focuses on ...
(Date:12/5/2018)... ... December 05, 2018 , ... Definitive Healthcare ... market, announced today that it was ranked #184 on Deloitte’s Technology Fast 500 ... highest growth in the fields of technology, media, telecommunications, life science, and energy ...
(Date:11/29/2018)... RATON, Fla. (PRWEB) , ... ... ... new study was published and released last month in the journal BMC ... security check point bins are crawling with infectious viruses that can cause ...
(Date:11/28/2018)... ... 28, 2018 , ... Shareholders Lori G. Cohen and Sara ... are speaking at the 23rd Annual American Conference Institute (ACI) Conference on Drug & ... Nov. 28 through Nov. 30 at the New York Marriott Marquis. The firm is ...
(Date:11/28/2018)... ... November 28, 2018 , ... CBD ... low-risk payment processing solution available. Previously, merchants were unable to obtain legitimate CBD ... even having to close down their business after being put on the Visa ...
Breaking Medicine News(10 mins):